 SEATTLE--BUSINESS WIRE--Silverback Therapeutics, Inc. Nasdaq: SBTX Silverback, a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Laura Shawver, Ph.D., S 